Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life
Open Access
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 327, 186-197
Abstract
No abstract availableKeywords
Funding Information
- Schweizerische Nationalfonds (31003A_170134)
This publication has 49 references indexed in Scilit:
- Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and TherapyAnnual Review of Pharmacology and Toxicology, 2015
- PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteinsProtein Engineering, Design and Selection, 2013
- On-target and Off-target-based Toxicologic EffectsToxicologic Pathology, 2012
- Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent mannerNature Nanotechnology, 2012
- A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor ActivityClinical Cancer Research, 2011
- HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [99mTc(CO)3]+, and Shows Improved Biodistribution with Reduced Hepatic Radioactivity AccumulationBioconjugate Chemistry, 2010
- Structure and function of immunoglobulinsJournal of Allergy and Clinical Immunology, 2010
- A modeling analysis of the effects of molecular size and binding affinity on tumor targetingMolecular Cancer Therapeutics, 2009
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearanceAdvanced Drug Delivery Reviews, 2008
- Engineering and characterization of a superfolder green fluorescent proteinNature Biotechnology, 2005